A new international study sheds light on the urgent need to improve diagnostic accuracy for children with cancer in low- and middle-income countries (LMICs), emphasizing the transformative potential of sequencing-based technologies in pediatric oncology.

Led by a Global Research Team

The research was led by Dr. Kenneth M. Busby , in collaboration with a diverse group of global experts including Dr. Nathaniel Webb, Dr. Javeria Aijaz, Dr. Federico Antillon-Klussmann, Dr. Vaskar Saha, Dr. Rui M. Reis, Dr. Gevorg Tamamyan, Dr. Patricia Alcasabas, Dr. Eva Cutiongco-de la Paz, Dr. Jamie Zeal, Dr. Dylan Graetz, Dr. Nickhill Bhakta, Dr. Angelo Navas, Dr. Samantha Rubio, Dr. Stuart Rennie, Dr. Thomas B. Alexander, and Dr. Megan C. Roberts.

Their collective work focuses on understanding the real-world challenges and opportunities of implementing advanced diagnostic tools in resource-constrained settings.

The Challenge: Inaccurate Diagnosis in Pediatric Cancer

In many LMICs, imprecise or delayed diagnosis remains a leading cause of treatment failure in pediatric cancer. Limited access to advanced diagnostic tools often results in misclassification of cancers, directly impacting treatment outcomes and survival rates.

This study explores how diagnostic sequencing technology—a method that analyzes genetic information to accurately classify cancers—can address these critical gaps.

Study Approach

Researchers conducted 39 in-depth virtual interviews with pediatric oncology professionals across six hospitals in LMICs. Using the Consolidated Framework for Implementation Research (CFIR), the study identified key facilitators and barriers influencing the adoption of sequencing-based diagnostics.

Key Facilitators: What’s Driving Change?

The study highlights several encouraging factors that can support implementation:

Strong recognition of the relative advantage of sequencing technologies
Positive organizational culture and willingness to innovate
High levels of self-efficacy and collective motivation among healthcare teams
Increasing awareness of patient needs and diagnostic gaps
Active leadership engagement and support
Growing knowledge and belief in the value of precision diagnostics

These factors indicate that many centers in LMICs are not only aware of the problem but are also motivated to adopt innovative solutions.

Key Barriers: What’s Holding Progress Back?

Despite the optimism, several critical challenges remain:

High costs of sequencing technologies
Limited availability of resources and infrastructure
Challenges in maintaining long-term sustainability
Difficulty in engaging stakeholders and participants
Uncertainty around funding sources and continuity

These barriers highlight the complexity of implementing advanced technologies in settings where healthcare systems are already under strain.

A Call for Global Collaboration

One of the most important takeaways from the study is the need for innovative global partnerships. Researchers emphasize that while the motivation and readiness exist within LMICs, external support, collaboration, and investment are essential to scale these solutions effectively.

Why This Matters

Improving diagnostic accuracy is not just a technical upgrade—it is a life-saving intervention. For children with cancer, timely and precise diagnosis can mean the difference between effective treatment and avoidable complications.

Conclusion

The study underscores a powerful message: LMICs are ready for change, but they cannot do it alone. By addressing resource gaps and fostering global partnerships, sequencing-based diagnostics can become a reality—bringing hope, precision, and better outcomes to pediatric cancer care worldwide.